Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making

INTRODUCTION: Access and funding for newly approved treatments for non-small cell lung cancer (NSCLC) are often dependent on Health Technology Assessment (HTA) involving cost-effectiveness analysis. Whilst methods used by HTA agencies share many similarities, final decisions may differ. This may be...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Jason, Stainthorpe, Angela, Jones, Beverley, Jacob, Ian, Hertel, Nadine, Diaz, Jose, Yuan, Yong, Borrill, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611140/
https://www.ncbi.nlm.nih.gov/pubmed/34216002
http://dx.doi.org/10.1007/s41669-021-00279-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611140/
https://www.ncbi.nlm.nih.gov/pubmed/34216002
http://dx.doi.org/10.1007/s41669-021-00279-2

Ejemplares similares